CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis
and are not recommended to receive adjuvant chemotherapy after radical surgery. With the
advances in liquid biopsy technology, detection of circulating tumor DNA (ctDNA) can
effectively identify early-stage cancer patients with minimal residual disease (MRD) after
surgery. According to the growing number of MRD studies in solid tumor, colorectal cancer
patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse
within two years. This study aims to assess the efficacy of adjuvant chemotherapy with
capecitabine plus oxaliplatin (CAPEOX) compared with conventional observation in MRD-positive
patients with stage I colorectal cancer and clinically low-risk stage II colon cancer.